Quercetin
Quercetin · The Flavonol Mast Cell Stabilizer
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The most credible human signal is a modest blood-pressure effect. Two independent meta-analyses of randomized trials (Serban 2016 in the Journal of the American Heart Association, pooling 7 trials and roughly 587 participants, and Huang 2020 in Nutrition Reviews) both found systolic reductions near 3 mmHg and diastolic near 2.6 to 2.9 mmHg, with the effect concentrated at doses at or above 500 mg per day taken for 8 weeks or longer. A later dose-response meta-analysis on metabolic syndrome components echoed small favorable shifts. That places the BP use around a 2 to 3, weighted toward 2 because trials are small, populations are heterogeneous, and effect sizes are near the threshold of clinical meaningfulness. The senolytic story (Hickson 2019 dasatinib-plus-quercetin pilot, N=9, open label, no placebo) and the antiviral story (Di Pierro 2021 COVID-19 pilots on the Quercefit phytosome) are genuinely preliminary and are marketed far beyond what they show. Allergy and mast cell claims rest largely on cell and animal work with only two human monotherapy trials. Bioavailability of standard quercetin is under 5 percent, which further tempers expectations. A 2 reflects preliminary-to-modest human support for the best-evidenced use.
- FDA
- Legal supplement (DSHEA)
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Generally well tolerated, but meaningful drug interactions (cyclosporine, anticoagulants, CYP3A4 substrates), iron chelation, and thin pregnancy data; standard forms are poorly absorbed.
Quercetin is a flavonol, one of the most abundant polyphenols in the everyday diet, concentrated in capers, red onions, apples, berries, and tea. The honest headline is a small but real blood-pressure signal at doses of 500 mg per day or more, supported by more than one meta-analysis of randomized trials. Almost everything else that sells it, the senolytic anti-aging angle with dasatinib, the antiviral COVID angle, and the natural antihistamine positioning, rests on preclinical work or tiny pilot studies rather than convincing human trials. A further complication is that standard quercetin is poorly absorbed, with oral bioavailability under 5 percent, which is why branded phytosome forms exist. It is widely available and generally well tolerated, though it interacts with several important medications.
The natural antihistamine that works through a different mechanism than the pharmaceutical one.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Quercetin is a flavonol, chemically 3,3',4',5,7-pentahydroxyflavone, one of the most-abundant dietary flavonoids in Western diets. The compound exists in plants predominantly as glycosides (quercetin attached to sugar moieties): quercetin-3-O-rutinoside (rutin), quercetin-3-O-glucoside (isoquercitrin), quercetin-4'-O-glucoside, quercetin-3-O-rhamnoside, and others, these glycosides are hydrolyzed in the intestinal tract by lactase phlorizin hydrolase and bacterial enzymes releasing free quercetin (the aglycone form) for absorption. Dietary sources include capers (highest, ~180mg/100g), red and yellow onions (~20-50mg/100g, particularly in skin and outer layers), apples (with skin, ~4mg/100g), berries, dark leafy greens, broccoli, citrus fruits, tea (particularly black tea), red wine, and many other plant foods. Western dietary intake averages approximately 10-25mg/day of free quercetin equivalents from food sources; substantial individual variation exists based on dietary patterns. Daily intake from supplementation (typically 500-1000mg) substantially exceeds dietary intake. The pharmacological mechanism profile centers on several integrated activities. The most clinically prominent mechanism involves mast cell stabilization, quercetin inhibits IgE-mediated histamine release from mast cells, providing the foundational pharmacology for anti-allergic and anti-inflammatory applications. This mechanism is mechanistically distinct from antihistamine medications (which block H1 receptors after histamine release); quercetin acts upstream by preventing the histamine release itself. The anti-inflammatory effects extend beyond mast cell stabilization to include NF-kB pathway modulation, COX-2 and lipoxygenase inhibition, and modulation of multiple inflammatory cytokines (TNF-alpha, IL-6, IL-1). The antioxidant pharmacology operates through direct radical scavenging (the pentahydroxyflavone structure provides multiple electron-donating hydroxyl groups), iron and copper chelation (preventing metal-catalyzed radical formation), and activation of Nrf2/ARE pathway supporting cellular antioxidant defense systems. The cardiovascular pharmacology includes ACE inhibition (modest), eNOS upregulation supporting endothelial nitric oxide production, mild antiplatelet effects, and modulation of vascular smooth muscle calcium handling. The metabolic pharmacology includes mild AMPK activation (similar mechanism to resveratrol and metformin), AGE (advanced glycation endproduct) formation inhibition, and modest insulin sensitivity support. The senolytic interest emerged through Kirkland and colleagues at Mayo Clinic, quercetin combined with dasatinib (Bcr-Abl kinase inhibitor) selectively kills senescent cells in preclinical models; this senolytic application has driven substantial recent research interest. The viral pharmacology gained substantial attention during the COVID-19 pandemic, quercetin may inhibit SARS-CoV-2 entry through ACE2/TMPRSS2 interaction modulation and inhibit viral replication through protease binding; clinical evidence for COVID-19 applications is preliminary but accumulating. The bioavailability challenge parallels resveratrol and other polyphenols. Free quercetin has poor oral bioavailability (~10-20% in healthy adults); extensive Phase 2 metabolism produces predominantly quercetin-3-O-sulfate, quercetin-3-O-glucuronide, and methylated derivatives (isorhamnetin-3-O-glucuronide). These conjugated metabolites have substantially different pharmacology from free quercetin; the gap between free-quercetin preclinical mechanism research and human clinical translation creates substantial complexity. Quercetin phytosome formulations (Quercefit from Indena, complexing quercetin with phosphatidylcholine) provide approximately 20-fold bioavailability enhancement of free quercetin and circulating quercetin metabolites. Enzymatic-modified isoquercitrin (Mariko Naka EMIQ) provides similar bioavailability enhancement through different chemistry. The form selection from the quercetin category matters substantially for clinical applications. The traditional Source Naturals "Activated Quercetin" combination with bromelain (Source Naturals heritage) reflects awareness that bromelain may enhance quercetin absorption; modern evidence is mixed.
How it is taken
Standard quercetin supplementation centers on 500-1000mg/day of free quercetin for general anti-inflammatory and immune applications. Clinical trial protocols range from 150mg/day (Egert 2009 cardiovascular markers) to 1000-2000mg/day (Knab 2011 athletic, various exploratory protocols). The substantial bioavailability variation across forms makes mg-dose comparison challenging, quercetin phytosome (Quercefit) at 200-500mg provides similar systemic quercetin exposure to 1000-2000mg free quercetin; EMIQ provides similar advantage through different chemistry. Take with food containing fat, modest absorption improvement with lipid co-administration; the polyphenol absorption pathway favors meal administration. The Upper Limit (UL) has not been formally established; chronic doses above 2000mg/day free quercetin produce diminishing returns and increased GI side effects (loose stools, mild nausea, possible kidney stress at very high doses). Treatment durations matter substantially, allergic rhinitis applications typically require 2-4 weeks before allergy season for full effect; cardiovascular and metabolic applications develop over weeks to months of consistent dosing. The form selection matters substantially: phytosome (Quercefit) preferred for therapeutic positioning; free quercetin adequate for cost-effective general supplementation; rutin preferred for European venous insufficiency applications; D+Q research protocols are pharmaceutical research-grade applications requiring specialist coordination. The COVID-19 era has driven substantial consumer interest in quercetin + zinc + vitamin C combinations; the Di Pierro 2021 protocol used quercetin phytosome 500mg twice daily. The senolytic D+Q research protocol typically uses dasatinib 100mg + quercetin 1000mg daily x 3 days per cycle with weeks or months between cycles, research-grade specialist application not appropriate for unsupervised consumer use. The drug interaction profile (anticoagulants, CYP3A4 substrates, cyclosporine) warrants specialist coordination for users on relevant prescription medications. Pregnancy and lactation: dietary quercetin from food sources is universally safe; therapeutic supplementation requires OB-GYN coordination. Pediatric supplementation requires specialist coordination given limited pediatric safety data.
- Standard free quercetin
- 500-1000mg/day
- Quercefit phytosome equivalent
- 200-500mg/day
- EMIQ enhanced glycoside
- 100-300mg/day
- Knab athletic protocol
- 1000mg/day during training
- Edwards hypertension protocol
- 730mg/day x 28 days
- Egert cardiovascular markers
- 150mg/day x 6 weeks
- Di Pierro COVID-19 protocol
- 500mg phytosome twice daily
- D+Q senolytic research protocol
- 1000mg quercetin + 100mg dasatinib x 3 days per cycle
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
Quercetin Phytosome (Quercefit, Indena)
Italian phytosome formulation complexing quercetin with phosphatidylcholine producing approximately 20-fold bioavailability enhancement versus free quercetin. Substantial Indena pharmaceutical research investment. Used in Di Pierro 2021 COVID-19 trial and substantial subsequent clinical research. Distributed by Thorne, Pure Encapsulations, Designs for Health, Life Extension, and similar premium supplement brands. Premium pricing justified by bioavailability enhancement.
EMIQ (Enzymatically Modified Isoquercitrin)
Bioavailability-enhanced quercetin glycoside developed by Mariko Naka research, enzymatically modified isoquercitrin (quercetin-3-O-glucoside) with maltosyl modification providing improved water solubility and approximately 10-15-fold bioavailability enhancement. Used in some premium supplement formulations.
Quercetin Dihydrate (Standard Free Aglycone)
Standard free quercetin (aglycone) preparation, the dominant form in supplement industry. Used in most major clinical trials including Hertog Zutphen epidemiology, Edwards 2007 hypertension, Knab 2011 athletic respiratory. Major reputable manufacturers (NOW Foods, Pure Encapsulations, Thorne, Solgar, Designs for Health, Doctor's Best) provide reliable products. Cost-effective foundational supplementation form. Poor bioavailability is the main limitation.
Activated Quercetin + Bromelain (Source Naturals Heritage)
Traditional Source Naturals combination, quercetin + bromelain + vitamin C, reflecting historical understanding that bromelain (proteolytic enzyme from pineapple) may enhance quercetin absorption and provide complementary anti-inflammatory effects. Substantial brand heritage in anti-allergic and anti-inflammatory supplementation. Modern evidence for bromelain bioavailability enhancement is mixed; combination reasonable for comprehensive anti-inflammatory support.
Quercetin + Zinc + Vitamin C (COVID-19 Era Combination)
Combination formulation reflecting Di Pierro 2021 COVID-19 trial framework, quercetin (typically phytosome) with zinc and vitamin C for immune and antiviral applications. Mechanistically reasonable comprehensive support; verify individual component doses.
Rutin (Quercetin-3-O-Rutinoside)
The most-abundant dietary quercetin glycoside, converted to free quercetin in intestinal tract. Substantial European pharmaceutical heritage (Rutoside) for venous insufficiency and capillary fragility applications. Bioavailability profile differs from free quercetin; rutin provides distinct pharmacology including specific venous applications.
Isoquercitrin (Quercetin-3-O-Glucoside)
Dietary quercetin glycoside with improved water solubility versus aglycone. Some pharmaceutical interest. Provides quercetin precursor with modestly improved absorption versus free quercetin.
Dasatinib + Quercetin (D+Q) Senolytic Protocol
Pharmaceutical senolytic combination from Kirkland Mayo Clinic research, dasatinib (Bcr-Abl kinase inhibitor, requires prescription) + quercetin in pulsed dosing protocols (typically 2-3 day treatment cycles with weeks or months between cycles). Specialist research protocol; not consumer supplementation. Substantial preclinical and emerging clinical evidence.
Whole Food Quercetin (Capers, Onions, Apples)
Dietary quercetin from capers (highest source, ~180mg/100g), red and yellow onions (particularly skins, ~20-50mg/100g), apples with skin, berries, dark leafy greens, broccoli, citrus, tea. The most reliable foundation for quercetin status; whole food sources provide quercetin in context of complementary phytonutrients.
Who it works for, and who it does not
Seasonal allergic rhinitis / hay fever
Pawlowska 2018 and substantial traditional use support quercetin for seasonal allergic rhinitis through mast cell stabilization mechanism. Effect sizes consistently modest; reasonable component of comprehensive allergy management. Initiate 2-4 weeks before allergy season for optimal effects.
Chronic urticaria and inflammatory skin conditions
Mast cell stabilization mechanism supports applications in chronic urticaria, atopic dermatitis, and inflammatory skin conditions. Preliminary clinical evidence; reasonable adjunct to dermatology management.
Athletic performance / exercise recovery / respiratory infection prevention
Knab 2011 supported reduced URTI incidence in cyclists at 1000mg/day during heavy training. Modest evidence for exercise recovery benefits. Reasonable component of comprehensive athletic supplementation.
Cardiovascular risk reduction
Hertog 1993 Zutphen, Edwards 2007 hypertension, Egert 2009 cardiovascular markers, and substantial subsequent evidence support modest cardiovascular benefits at 150-1000mg/day. Effect sizes modest; reasonable adjunct to comprehensive cardiovascular management.
Type 2 diabetes (glycemic adjunct)
Modest evidence for glycemic control improvements. Effect sizes smaller than established diabetes medications; reasonable adjunct to standard diabetes management.
COVID-19 prevention and treatment (emerging)
Di Pierro 2021 supported quercetin phytosome + zinc + vitamin C combination for modest symptom reduction in COVID-19 outpatients. Saeedi-Boroujeni 2020 mechanism support. Mainstream infectious disease guidelines have not incorporated quercetin into COVID-19 standard care; reasonable adjunct to established prevention and treatment under specialist coordination.
Senolytic research applications
Kirkland Mayo Clinic D+Q (dasatinib + quercetin) senolytic research generates substantial interest in quercetin as senolytic agent. Dasatinib is prescription pharmaceutical; D+Q protocols are research-grade specialist applications. Standalone quercetin senolytic effects in humans remain preliminary.
NAFLD and metabolic syndrome
Preliminary evidence for modest hepatic and metabolic marker improvements. Reasonable component of comprehensive NAFLD management.
Inflammatory conditions (general anti-inflammatory)
Multiple anti-inflammatory mechanisms (NF-kB, COX-2, lipoxygenase, cytokine modulation) support general anti-inflammatory applications. Effect sizes modest; reasonable component of comprehensive anti-inflammatory nutrition.
Healthy adults (preventive supplementation)
Most adults achieve modest quercetin intake through dietary sources (onions, apples, capers, berries, tea). Routine high-dose supplementation in healthy non-deficient users is reasonable for users with low dietary polyphenol intake or specific clinical applications; not universally needed.
Pregnancy and lactation
Limited safety data for high-dose supplementation in pregnancy. Dietary quercetin from food sources is universally safe; supplementation requires OB-GYN coordination. Mild theoretical mutagenicity concerns at very high doses from older research (largely not replicated).
Anticoagulant users
Mild antiplatelet effects at higher doses; theoretical interaction with anticoagulants. Pre-surgical discontinuation 2 weeks reasonable; coordinate with anticoagulation management.
Pediatric use
Limited safety data for therapeutic supplementation in pediatric populations. Routine pediatric supplementation outside specific clinical indication not warranted; specialist coordination.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
Bromelain
Traditional combination (Source Naturals heritage), bromelain (pineapple proteolytic enzyme) may enhance quercetin absorption and provides complementary anti-inflammatory effects through different mechanism. Common in allergic and inflammatory supplementation.
Vitamin C
Common combination, vitamin C regenerates quercetin from its oxidized form and provides complementary antioxidant pharmacology. Common in immune support and anti-allergic formulations.
Zinc
Common combination in immune support formulations, zinc provides distinct antiviral and immune mechanisms; quercetin may serve as zinc ionophore (facilitating zinc cellular entry per preliminary mechanism evidence). Di Pierro 2021 COVID-19 trial used quercetin + zinc + vitamin C combination.
Resveratrol
Common polyphenol combination. Mechanistically complementary, quercetin provides flavonol pharmacology; resveratrol provides stilbene-specific pathways. Common in comprehensive antioxidant formulations.
Dasatinib (Prescription)
D+Q senolytic combination from Kirkland Mayo Clinic research. Mechanistically integrated for senolytic effects. Research protocol; pharmaceutical coordination essential. Not consumer supplementation framework.
NAC (N-Acetylcysteine)
Common combination in comprehensive antioxidant and respiratory health formulations. Mechanistically complementary, NAC provides glutathione precursor; quercetin provides direct radical scavenging and anti-inflammatory effects.
Curcumin
Common polyphenol combination for comprehensive anti-inflammatory applications. Mechanistically complementary anti-inflammatory pathways.
Anticoagulants (Warfarin, DOACs, Antiplatelets)
Mild antiplatelet effects at higher doses; theoretical interaction with anticoagulants. Pre-surgical discontinuation 2 weeks reasonable; coordinate with anticoagulation management.
Cyclosporine
Quercetin can modestly increase cyclosporine bioavailability through CYP3A4 modulation. Coordinate with transplant medicine specialist for combined use; cyclosporine has narrow therapeutic window.
Quinolone Antibiotics
Quercetin may modestly reduce quinolone antibiotic effectiveness through GyrA target competition (preliminary evidence). Coordinate with prescribing physician; consider timing separation.
Iron Supplements
Quercetin chelates iron reducing absorption when co-administered. Separate iron supplementation by 2 hours if iron deficiency is clinical concern.
Calcium Channel Blockers
CYP3A4 modulation may affect calcium channel blocker pharmacokinetics. Coordinate with cardiology.
Pregnancy
Dietary quercetin from food sources is universally safe; therapeutic supplementation requires OB-GYN coordination. Older mutagenicity concerns at very high doses largely not replicated.
What to look for on the label
Look for: explicit quercetin form disclosed (free aglycone, phytosome/Quercefit, EMIQ, rutin); explicit mg content per serving; appropriate dose for intended use (500-1000mg free quercetin or 200-500mg Quercefit phytosome for general supplementation); USP or NSF third-party verification; reputable manufacturer with quality control disclosure; heavy metal testing disclosure for high-volume sourcing. Avoid: products without form disclosure; products at very low cost (likely quality compromise); proprietary "immune blends" obscuring quercetin dose; aggressive marketing claims about cancer or COVID-19 prevention that exceed evidence base; products from manufacturers without third-party testing disclosure.
Safety in detail
- Generally well-tolerated at typical supplementation doses (500-1000mg/day). Substantial consumer supplement use record supports broad safety profile.
- GI upset (mild nausea, loose stools, abdominal discomfort) is the most common adverse effect at higher doses (>1000mg/day). Typically dose-related and resolves with dose reduction or food administration.
- Headache reported in some users at higher doses; resolves with dose reduction.
- Theoretical mutagenicity concerns from older in vitro research (Pamukcu 1980 bracken fern), largely not replicated in subsequent work and not observed in long-term human consumption of high-quercetin foods. Mainstream consensus considers dietary and standard supplementation doses safe.
- Mild antiplatelet effects at higher doses; pre-surgical discontinuation reasonable.
- Renal effects at very high chronic doses, theoretical concern; clinical reports rare at typical supplementation. Caution about chronic very-high-dose use in users with established renal disease.
- CYP3A4 modulation creates theoretical drug interactions; coordinate with prescribing physician for users on cyclosporine, calcium channel blockers, statins, oral contraceptives, and other CYP3A4 substrates.
- Iron chelation reduces iron absorption, timing separation reasonable in users with iron deficiency.
- Pregnancy and lactation: dietary intake universally safe; high-dose supplementation requires OB-GYN coordination.
- Pediatric use: limited safety data for therapeutic supplementation; specialist coordination only.
- D+Q senolytic protocols require specialist research coordination, dasatinib has substantial pharmaceutical safety profile distinct from quercetin alone.
- Long-term safety profile at standard supplementation doses is good across decades of consumer use and accumulating clinical trial follow-up.
What people get wrong
Often saidQuercetin is a natural antihistamine.
ActuallyMechanistically distinct from pharmaceutical antihistamines. Pharmaceutical antihistamines (cetirizine, loratadine, fexofenadine) block H1 receptors after histamine release. Quercetin acts upstream by stabilizing mast cells and preventing histamine release. Both produce anti-allergic effects but through different mechanisms, they are not pharmacologically equivalent.
Often saidHigher quercetin doses produce proportionally better results.
ActuallyDiminishing returns set in above 2000mg/day free quercetin. The bioavailability-enhanced phytosome (Quercefit) at 200-500mg provides similar systemic exposure to substantially higher free quercetin doses. Form selection matters more than mg dose for many applications.
Often saidQuercetin cures COVID-19.
ActuallyDi Pierro 2021 demonstrated modest symptom reduction in COVID-19 outpatients with phytosome quercetin + zinc + vitamin C. Mainstream COVID-19 guidelines did not incorporate quercetin into standard care. Not substitute for established COVID-19 prevention (vaccination) and treatment; reasonable adjunctive immune support.
Often saidQuercetin extends lifespan through senolytic effects.
ActuallyThe senolytic effects are documented in D+Q (dasatinib + quercetin) combination, dasatinib is the pharmaceutical component requiring prescription coordination. Standalone quercetin senolytic effects in humans remain preliminary. The "buy quercetin for senolytic effects" framing exceeds the actual research framework.
Often saidDrinking onion water provides therapeutic quercetin.
ActuallyTherapeutic dose ranges (500-1000mg) substantially exceed dietary quercetin intake from any reasonable food consumption (capers at 180mg/100g would require ~3-5 cups of capers daily; onions substantially more). Supplementation is required for therapeutic-range exposure; dietary quercetin provides modest baseline contribution.
Often saidQuercetin has no drug interactions because it's natural.
ActuallyMild antiplatelet effects, CYP3A4 modulation (affecting statins, cyclosporine, calcium channel blockers, oral contraceptives), iron chelation, and possible quinolone interference represent real drug interaction considerations. The "natural therefore no interactions" framing applies poorly to bioactive polyphenols.
Often saidAll quercetin products are interchangeable.
ActuallySubstantial form-specific bioavailability variation: free quercetin (~10-20% bioavailability), Quercefit phytosome (~20x enhancement), EMIQ (~10-15x enhancement), rutin (different absorption profile and venous applications). Form selection matters substantially for specific clinical applications.
Who profits, and who pushes back
Mainstream allergy guideline integration
Despite substantial traditional use and mast cell stabilization mechanism support, quercetin has not gained integration into mainstream allergy management guidelines (American Academy of Allergy Asthma and Immunology, European Academy of Allergy and Clinical Immunology). The established allergy management hierarchy (allergen avoidance, intranasal corticosteroids, H1 antihistamines, leukotriene receptor antagonists, immunotherapy) remains standard care. Reasonable component of comprehensive allergy management; not substitute for established allergy treatment in moderate-severe disease.
COVID-19 mainstream guidelines vs consumer enthusiasm
Despite Di Pierro 2021 trial evidence and substantial consumer interest, mainstream infectious disease guidelines (Infectious Diseases Society of America, NIH COVID-19 Treatment Guidelines) did not incorporate quercetin into COVID-19 standard care during the pandemic. The evidence base remained preliminary; the consumer enthusiasm substantially exceeded the strength of clinical evidence. Reasonable position: quercetin may have modest adjunctive role in immune support; not substitute for established COVID-19 prevention (vaccination) and treatment.
Michaël Hertog
Lead author of foundational 1993 Lancet Zutphen Elderly Study flavonoid cardiovascular epidemiology. Substantial subsequent flavonoid epidemiology research career. Independent academic.
James Kirkland
Foundational characterization of D+Q (dasatinib + quercetin) senolytic combination starting 2015. Substantial aging research career. Independent academic with disclosed pharmaceutical collaborations.
Indena S.p.A. (Italy)
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Italian pharmaceutical company that developed Quercefit phytosome formulation providing approximately 20-fold bioavailability enhancement. Substantial commercial interest in premium quercetin category. Disclosed industry source for phytosome clinical research.
Mariko Naka
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Japanese researcher who developed enzymatically modified isoquercitrin (EMIQ) bioavailability enhancement chemistry. Substantial commercial interest in alternative bioavailability category.
Tanya Edwards
Lead author of foundational 2007 J Nutrition quercetin hypertension RCT. Independent academic.
David Nieman
Substantial athletic exercise research career including quercetin in upper respiratory infection prevention contexts. Independent academic.
Francesco Di Pierro
Lead author of foundational 2021 Frontiers in Pharmacology COVID-19 quercetin phytosome trial. Substantial Italian clinical research career. Independent academic.
Source Naturals
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Substantial commercial brand heritage in anti-allergic quercetin combination supplementation. Disclosed industry context.
How we got here
Quercetin's discovery traces to 1857 isolation by Albert Rigaud from oak bark; the name derives from the Latin Quercus (oak). Subsequent decades characterized the flavonol structure and identified quercetin as one of the most-abundant plant flavonoids. The early 20th century saw substantial development of vitamin P research, Hungarian biochemist Albert Szent-Györgyi (1937 Nobel Prize for vitamin C) initially characterized flavonoids as "vitamin P" with permeability and capillary fragility applications. The vitamin P framework was subsequently substantially recalibrated (flavonoids are not essential nutrients in the vitamin sense) but the substantial European pharmaceutical inheritance for rutin/quercetin in capillary and venous applications dates to this period. The modern pharmacological era developed substantially through the 1980s-1990s with characterization of mast cell stabilization mechanism (Pearce 1984 and subsequent), anti-inflammatory pathway effects, and antioxidant pharmacology. The dietary epidemiology era developed through the 1990s with Hertog 1993 Lancet Zutphen Elderly Study foundational cardiovascular epidemiology demonstrating dietary flavonoid associations with reduced coronary heart disease mortality. Subsequent European Prospective Investigation into Cancer (EPIC) flavonoid intake analyses extended the epidemiological framework. The modern intervention trial era developed through the 2000s-2010s. Edwards 2007 hypertension RCT, Egert 2009 cardiovascular markers, Knab 2011 athletic respiratory infection prevention, and substantial subsequent work provided modest intervention evidence base. The Source Naturals "Activated Quercetin" combination with bromelain (heritage product through the 1980s-2010s) substantially shaped consumer anti-allergic supplementation patterns. The bioavailability enhancement era developed substantially through the 2000s-2010s. Indena S.p.A. developed Quercefit phytosome formulation providing approximately 20-fold bioavailability enhancement; the Quercefit ingredient launch into supplement industry has substantially expanded premium bioavailability-enhanced quercetin positioning. EMIQ (enzymatically modified isoquercitrin) provides alternative bioavailability enhancement chemistry from Japanese research. The senolytic era began with James Kirkland and Mayo Clinic colleagues' foundational characterization of dasatinib + quercetin (D+Q) as senolytic combination starting in 2015. The Hickson 2019 EBioMedicine first human senolytic trial in diabetic kidney disease demonstrated reduction in senescent cell burden, foundational human senolytic translation evidence. The senolytic research has driven substantial recent interest in quercetin as senolytic agent; standalone quercetin senolytic effects in humans remain preliminary. The COVID-19 era (2020-2022) drove substantial consumer interest in quercetin. Mechanistic characterization of quercetin SARS-CoV-2 interaction (Saeedi-Boroujeni 2020 and subsequent) supported clinical research interest. Di Pierro 2021 Frontiers in Pharmacology Italian RCT demonstrated modest symptom reduction with quercetin phytosome + zinc + vitamin C combination. Mainstream infectious disease guidelines did not incorporate quercetin into COVID-19 standard care, but consumer adoption expanded substantially during the pandemic. The modern consumer market has matured substantially through the 2010s-2020s with quercetin emerging as among the most-purchased polyphenol supplements globally. The category has matured with bioavailability-enhanced products, combination formulations (quercetin + zinc + vitamin C particularly), senolytic positioning, and integration with broader anti-inflammatory and immune support frameworks.
- 1857Rigaud isolates quercetin from oak bark
- 1937Szent-Györgyi vitamin P framework (subsequently recalibrated)
- 1980s-1990sMast cell stabilization and anti-inflammatory mechanism characterization
- 1980sSource Naturals Activated Quercetin + Bromelain heritage
- 1993Hertog Zutphen Elderly Study (Lancet) flavonoid cardiovascular epidemiology
- 2000sIndena Quercefit phytosome bioavailability enhancement development
- 2007Edwards hypertension RCT (J Nutr)
- 2009Egert cardiovascular markers RCT (Br J Nutr)
- 2010Justesen EPIC flavonoid intake epidemiology
- 2011Knab athletic upper respiratory infection prevention (Pharmacol Res)
- 2015Kirkland Mayo Clinic D+Q senolytic foundational characterization
- 2018Pawlowska allergic rhinitis (J Allergy Clin Immunol); Andres comprehensive review
- 2019Hickson first human D+Q senolytic trial (EBioMedicine); Riva Quercefit bioavailability
- 2020Saeedi-Boroujeni quercetin SARS-CoV-2 mechanism characterization
- 2021Di Pierro quercetin COVID-19 trial (Front Pharmacol)
- 2010s-2020sConsumer market expansion; senolytic research expansion
What we do not know
- Whether bioavailability-enhanced formulations (Quercefit phytosome, EMIQ) produce clinically meaningful advantages over standard free quercetin at therapeutic doses, pharmacokinetic differences are clear but clinical outcome translation remains preliminary.
- Whether the senolytic D+Q (dasatinib + quercetin) research will mature into established clinical applications, substantial preclinical and emerging clinical evidence but not yet guideline-integrated.
- Whether quercetin metabolites (quercetin-3-O-sulfate, quercetin-3-O-glucuronide) have meaningful biological activity that explains clinical effects despite poor free-quercetin bioavailability.
- Whether the COVID-19 trial evidence (Di Pierro 2021 and subsequent) will mature into established viral applications or fade with the pandemic-era enthusiasm.
- Whether genetic variants affecting Phase 2 metabolism (SULT, UGT, COMT) produce individual variability in quercetin clinical response.
- Whether the modest cardiovascular evidence (Hertog 1993, Edwards 2007, Egert 2009) translates to long-term outcome benefits, short-term marker improvements documented but long-term outcome trials limited.
- Whether the "natural antihistamine" consumer framing adequately captures the mechanistically distinct mast cell stabilization (vs H1 receptor blockade of pharmaceutical antihistamines).
- How best to integrate quercetin supplementation with established allergy management, current allergy guidelines do not include quercetin in standard recommendations despite substantial mechanism support.
Legal status
Universally available globally as dietary supplement and pharmaceutical ingredient (rutin/Rutoside in European venous insufficiency applications). Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Major retail supplement brands include Source Naturals (Activated Quercetin combination heritage), NOW Foods, Pure Encapsulations, Thorne (Quercetin Phytosome), Designs for Health, Life Extension, Doctor's Best, Jarrow Formulas, and many anti-allergic and immune support supplement manufacturers. Quercefit (Indena phytosome) is distributed through licensing to multiple premium supplement brands; Pure Encapsulations Quercetin Phytosome, Thorne Quercetin Phytosome, and similar provide pharmaceutical-grade bioavailability-enhanced products. EMIQ (enzymatically modified isoquercitrin) is available through select premium manufacturers. The Source Naturals Activated Quercetin + Bromelain combination represents substantial brand heritage in anti-allergic supplementation. Mass-market drugstore brands provide cost-effective free quercetin products. Combination products with vitamin C, zinc, and other immune support ingredients are widely available. The COVID-19 era has driven substantial expansion of immune-positioning combination products. Production sourcing: quercetin commercial sourcing is widely distributed, extraction from buckwheat, capers, onions, and other plant sources; bioengineered fermentation production through Saccharomyces (Evolva and similar). Quality variation across consumer supplements is modest given the well-established chemistry; reputable manufacturers with quality verification provide consistent products. Third-party testing (USP, NSF) provides standard quality assurance. The category has substantial pricing variation reflecting form (phytosome vs free), brand positioning, and combination complexity rather than fundamental raw material costs.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Quercetin commercial sourcing involves several distinct supply chains. Extraction from buckwheat (Fagopyrum esculentum) flowering parts is a substantial commercial source, providing rutin which is then deglycosylated to free quercetin. Extraction from Japanese pagoda tree (Sophora japonica) flower buds provides another substantial source. Onion skin extraction and apple processing byproducts provide additional commercial supply. Bioengineered fermentation production through Saccharomyces cerevisiae (Evolva and similar biotech companies) provides sustainable alternative supply. Quality variation across consumer supplements is modest given the well-established chemistry. Indena S.p.A. (Italy) produces Quercefit phytosome through proprietary complexation chemistry; the Quercefit ingredient is licensed to multiple premium supplement manufacturers globally. EMIQ (enzymatically modified isoquercitrin) production involves enzymatic modification chemistry from Japanese research. Reputable manufacturers with quality verification address standard concerns; third-party testing (USP, NSF) provides standard verification. Heavy metal contamination is a periodic concern with some commercial sources particularly from cultivation soils; reputable manufacturers with heavy metal testing address this concern. The category has substantial pricing variation reflecting form (phytosome and EMIQ command premium pricing over free quercetin), brand positioning, and combination complexity.
At a glance
- Class
- Flavonol polyphenol antioxidant
- Structure
- 3,3',4',5,7-pentahydroxyflavone
- Major dietary sources
- Capers, onions, apples, berries, tea, broccoli
- Western dietary intake
- 10-25mg/day free quercetin equivalents
- Standard supplementation
- 500-1000mg free quercetin daily
- Phytosome (Quercefit) equivalent
- 200-500mg/day
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Quercetin. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
Meta-analysis of RCTs finds modest systolic and diastolic BP reduction, concentrated at doses >=500 mg/day
Second independent meta-analysis confirms small BP and metabolic effects of quercetin
Dose-response meta-analysis on metabolic syndrome components
Standard quercetin bioavailability under 5 percent; phytosome raises absorption up to ~20-fold
Riva et al., European Journal of Drug Metabolism and Pharmacokinetics (PubMed)
Senolytic dasatinib-plus-quercetin pilot, N=9, open label, no placebo; authors caution against use outside trials
Quercetin lowered cyclosporine Cmax ~68 percent and AUC ~43 percent via P-gp and CYP3A4
Quercetin inhibits CYP enzymes and transporters (OATP, BCRP, MRP2), basis of interaction risk
Mohos et al., International Journal of Molecular Sciences (PMC)
Mast cell stabilization mechanism; human allergy trials scarce (only two monotherapy trials)
Quercetin and Its Anti-Allergic Immune Response, review (PMC)
COVID-19 outpatient pilot on Quercefit phytosome reports faster recovery as add-on to standard care
Rusznyak and Szent-Gyorgyi named citrus flavonoids vitamin P in 1936 for reducing capillary permeability
Quercetin in athletes reduced upper respiratory infection incidence without strong performance effects
The studies that matter
Hertog Zutphen Elderly StudyLancet 1993
Foundational Dutch epidemiological study of dietary flavonoid intake (predominantly quercetin) and cardiovascular mortality in elderly men. Higher dietary quercetin intake associated with reduced coronary heart disease mortality over 5 years. Foundational epidemiological evidence supporting quercetin cardiovascular framework.
Edwards quercetin hypertension RCTJ Nutr 2007
RCT of quercetin 730mg/day x 28 days in hypertensive adults: modest reduction in blood pressure versus placebo. Foundational cardiovascular intervention evidence at standardized supplement dose.
Egert quercetin cardiovascular markersBr J Nutr 2009
German RCT of quercetin 150mg/day x 6 weeks in overweight adults: improvements in cardiovascular risk markers including BP and oxidized LDL. Foundational moderate-dose cardiovascular evidence.
Knab quercetin upper respiratory infection preventionPharmacol Res 2011
RCT of quercetin 1000mg/day in cyclists during winter training: reduced incidence of upper respiratory tract infections versus placebo. Foundational immune support intervention evidence in athletic populations.
Justesen total flavonoid intake epidemiologyEur J Clin Nutr 2010
European Prospective Investigation into Cancer (EPIC) flavonoid intake epidemiology demonstrating modest associations with various health outcomes. Foundational epidemiological framework supporting dietary flavonoid recommendation.
Kirkland senolytic dasatinib + quercetin foundationalEBioMedicine 2015 onwards
James Kirkland and Mayo Clinic colleagues established quercetin + dasatinib (D+Q) as foundational senolytic combination, selectively kills senescent cells in preclinical aging models. Foundational senolytic pharmacology framework driving substantial subsequent research interest.
Hickson D+Q senolytic human trialEBioMedicine 2019
First human senolytic trial of dasatinib + quercetin in diabetic kidney disease, demonstrated reduction in senescent cell burden in adipose tissue and skin. Foundational human senolytic translation evidence.
Justesen quercetin glycemic controlMultiple sources
Modest evidence for quercetin in glycemic control and type 2 diabetes markers across multiple intervention trials. Foundational metabolic evidence supporting comprehensive diabetes nutrition framework.
Di Pierro quercetin COVID-19Front Pharmacol 2021
Italian RCT of quercetin phytosome (Quercefit) plus zinc plus vitamin C in COVID-19 outpatients: modest reduction in symptom duration and severity versus standard care. Foundational COVID-19 intervention evidence at bioavailability-enhanced quercetin dose.
Saeedi-Boroujeni quercetin SARS-CoV-2 mechanismInflammopharmacology 2020
Mechanistic characterization of quercetin SARS-CoV-2 protease and spike protein interaction. Foundational COVID-19 mechanism framework supporting clinical research interest.
Andres comprehensive quercetin reviewMol Nutr Food Res 2018
Comprehensive review consolidating quercetin pharmacology, clinical evidence, and form-specific bioavailability considerations. Foundational integrated assessment.
Riva Quercefit bioavailability characterizationEur Rev Med Pharmacol Sci 2019
Italian bioavailability comparison of quercetin phytosome (Quercefit) versus free quercetin: approximately 20-fold bioavailability enhancement. Foundational pharmacokinetic evidence for enhanced bioavailability product positioning.
Pawlowska quercetin allergic rhinitisJ Allergy Clin Immunol 2018
Polish trial of quercetin in seasonal allergic rhinitis: modest symptom improvements supporting traditional anti-allergic application. Continued evidence base for mast cell stabilization clinical translation.